Revital Amiaz, Ilan Kent, Katya Rubinstein, Ben Ami Sela, Daniel Javitt, Mark Weiser
{"title":"开放标签肌氨酸用于精神分裂症抗精神病治疗的安全性、耐受性和药代动力学——初步研究。","authors":"Revital Amiaz, Ilan Kent, Katya Rubinstein, Ben Ami Sela, Daniel Javitt, Mark Weiser","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypofunction of NMDA receptor-mediated neurotransmission might play a critical role in schizophrenia. Sarcosine, N- methylglycine and inhibitor of the glycine transporter-1 (Gly-T1), has been suggested as a novel treatment for schizophrenia.</p><p><strong>Methods: </strong>Open label sarcosine was added to 22 stabilized patients: 5 patients received 2 gm/d, and 17 received 4gm/d. Pharmacokinetics samples, clinical and cognitive parameters using PANSS, CGI and MCCB were collected for all patients.</p><p><strong>Results: </strong>Significant improvement was observed after one week of treatment on PANSS sub-scale of 'positive symptoms' (Z= -2.68; P=0.007) and 'general psychopathology' (Z= -3.02; P=0.003), an improvement in PANSS total score and CGI-S showed a trend (Z= -2.72; P=0.06; Z=-2.69; P=0.08). Speed of processing (MCCB subscale) improved significantly (Z=-2.13; P=0.03). Sarcosine exhibited linear kinetics, with a Tmax and t½ of ~1½- 2½ hr and ~1hr, respectively.</p><p><strong>Limitations: </strong>This was a short period, open label pilot study with small sample size per dosage group.</p><p><strong>Conclusions: </strong>Sarcosine is a safe compound and might be efficacious in the treatment of schizophrenia.</p>","PeriodicalId":49288,"journal":{"name":"Israel Journal of Psychiatry and Related Sciences","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study.\",\"authors\":\"Revital Amiaz, Ilan Kent, Katya Rubinstein, Ben Ami Sela, Daniel Javitt, Mark Weiser\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hypofunction of NMDA receptor-mediated neurotransmission might play a critical role in schizophrenia. Sarcosine, N- methylglycine and inhibitor of the glycine transporter-1 (Gly-T1), has been suggested as a novel treatment for schizophrenia.</p><p><strong>Methods: </strong>Open label sarcosine was added to 22 stabilized patients: 5 patients received 2 gm/d, and 17 received 4gm/d. Pharmacokinetics samples, clinical and cognitive parameters using PANSS, CGI and MCCB were collected for all patients.</p><p><strong>Results: </strong>Significant improvement was observed after one week of treatment on PANSS sub-scale of 'positive symptoms' (Z= -2.68; P=0.007) and 'general psychopathology' (Z= -3.02; P=0.003), an improvement in PANSS total score and CGI-S showed a trend (Z= -2.72; P=0.06; Z=-2.69; P=0.08). Speed of processing (MCCB subscale) improved significantly (Z=-2.13; P=0.03). Sarcosine exhibited linear kinetics, with a Tmax and t½ of ~1½- 2½ hr and ~1hr, respectively.</p><p><strong>Limitations: </strong>This was a short period, open label pilot study with small sample size per dosage group.</p><p><strong>Conclusions: </strong>Sarcosine is a safe compound and might be efficacious in the treatment of schizophrenia.</p>\",\"PeriodicalId\":49288,\"journal\":{\"name\":\"Israel Journal of Psychiatry and Related Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Israel Journal of Psychiatry and Related Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Israel Journal of Psychiatry and Related Sciences","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study.
Background: Hypofunction of NMDA receptor-mediated neurotransmission might play a critical role in schizophrenia. Sarcosine, N- methylglycine and inhibitor of the glycine transporter-1 (Gly-T1), has been suggested as a novel treatment for schizophrenia.
Methods: Open label sarcosine was added to 22 stabilized patients: 5 patients received 2 gm/d, and 17 received 4gm/d. Pharmacokinetics samples, clinical and cognitive parameters using PANSS, CGI and MCCB were collected for all patients.
Results: Significant improvement was observed after one week of treatment on PANSS sub-scale of 'positive symptoms' (Z= -2.68; P=0.007) and 'general psychopathology' (Z= -3.02; P=0.003), an improvement in PANSS total score and CGI-S showed a trend (Z= -2.72; P=0.06; Z=-2.69; P=0.08). Speed of processing (MCCB subscale) improved significantly (Z=-2.13; P=0.03). Sarcosine exhibited linear kinetics, with a Tmax and t½ of ~1½- 2½ hr and ~1hr, respectively.
Limitations: This was a short period, open label pilot study with small sample size per dosage group.
Conclusions: Sarcosine is a safe compound and might be efficacious in the treatment of schizophrenia.
期刊介绍：
THE ISRAEL JOURNAL OF PSYCHIATRY publishes original articles dealing with the all bio-psycho-social aspects of psychiatry. While traditionally the journal has published manuscripts relating to mobility, relocation, acculturation, ethnicity, stress situations in war and peace, victimology and mental health in developing countries, papers addressing all aspects of the psychiatry including neuroscience, biological psychiatry, psychopharmacology, psychotherapy and ethics are welcome. The Editor also welcomes pertinent book reviews and correspondence. Preference is given to research reports of no more than 5,000 words not including abstract, text, references, tables and figures. There should be no more than 40 references and 4 tables or figures. Brief reports (1,500 words, 5 references) are considered if they have heuristic value. Books to be considered for review should be sent to the editorial office. Selected book reviews are invited by the editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
